INT190691

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2006
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 12
Total Number 14
Disease Relevance 15.90
Pain Relevance 0.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (APOA1) small molecule metabolic process (APOA1) extracellular region (APOA1)
plasma membrane (APOA1) enzyme binding (APOA1) transmembrane transport (APOA1)
Anatomy Link Frequency
liver 1
fibroblasts 1
adipocytes 1
APOA1 (Homo sapiens)
Pain Link Frequency Relevance Heat
fibrosis 363 92.48 High High
Inflammation 62 29.48 Quite Low
corticosteroid 10 27.04 Quite Low
alcohol 59 12.00 Low Low
imagery 9 5.00 Very Low Very Low Very Low
Pain 8 5.00 Very Low Very Low Very Low
aspirin 4 5.00 Very Low Very Low Very Low
withdrawal 4 5.00 Very Low Very Low Very Low
Angina 4 5.00 Very Low Very Low Very Low
anesthesia 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 187 100.00 Very High Very High Very High
Systemic Sclerosis 107 99.68 Very High Very High Very High
Cardiovascular Disease 83 99.48 Very High Very High Very High
Alcoholic Liver Diseases 39 98.76 Very High Very High Very High
Fatty Liver 174 98.56 Very High Very High Very High
Nash(non-alcoholic Steatohepatitis) 333 98.40 Very High Very High Very High
Hepatitis 69 98.28 Very High Very High Very High
Cirrhosis 96 97.68 Very High Very High Very High
Obesity 191 97.24 Very High Very High Very High
Necrosis 15 96.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Laboratory testing showed a significant decrease in homocysteine (P = 0.05), HDL cholesterol (P = 0.025) and Apo A (P = 0.004), as well as a significant increase in ?
Negative_regulation (decrease) of Apo A associated with disorder of lipid metabolism
1) Confidence 0.42 Published 2007 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Abstract Doc Link PMC2176151 Disease Relevance 0.51 Pain Relevance 0
Table 3 shows that compared with baseline, at the end of 24 months of follow-up there was a significant decrease in homocysteine (P < 0.05), HDL cholesterol (P = 0.025) and Apo A (P = 0.004).
Negative_regulation (decrease) of Apo A associated with disorder of lipid metabolism
2) Confidence 0.42 Published 2007 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2176151 Disease Relevance 0.52 Pain Relevance 0
Further analysis was performed on serum samples in an outside laboratory to compare apolipoprotein A and B levels after each washout period and after each six-week treatment.
Negative_regulation (compare) of apolipoprotein A associated with disorder of lipid metabolism
3) Confidence 0.41 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2803170 Disease Relevance 0.44 Pain Relevance 0
In the second case the absolute value of ApoA1 was not decreased (1.72 g/L) but was relatively low in comparison with HDL cholesterol (1.64 mmol/L).
Neg (not) Negative_regulation (decreased) of ApoA1 associated with disorder of lipid metabolism
4) Confidence 0.38 Published 2006 Journal BMC Gastroenterol Section Body Doc Link PMC1657015 Disease Relevance 1.92 Pain Relevance 0.04
The same associations were observed for proteins in univariate analysis with a decrease in ApoA1, haptoglobin and an increase of A2M in NASH.
Negative_regulation (decrease) of ApoA1 associated with nash(non-alcoholic steatohepatitis)
5) Confidence 0.38 Published 2006 Journal BMC Gastroenterol Section Body Doc Link PMC1657015 Disease Relevance 1.91 Pain Relevance 0.03
ApoA1 was decreased in group A compared to starting values (p = 0,055) and remained unchanged in group B.
Negative_regulation (decreased) of ApoA1
6) Confidence 0.35 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2768711 Disease Relevance 0.37 Pain Relevance 0
Moreover, treatment with PKA and adenylate cyclase inhibitors does not lead to a reduction in apoA-I induced cholesterol release (figure 2).
Negative_regulation (reduction) of apoA-I
7) Confidence 0.35 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.38 Pain Relevance 0
Finally, it is also known that PKC activators are capable of activating cholesterol efflux in fibroblasts, vascular smooth muscle cells, and in human macrophages [14,15], whereas inhibitors of PKC lead to a reduction in apoA-I induced efflux [16].
Negative_regulation (reduction) of apoA-I in fibroblasts
8) Confidence 0.34 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.31 Pain Relevance 0
However, following 24 h treatment with the statins (data not shown), concomitantly or not with apoA-I, the release of cholesterol into the medium decreases significantly, clearly demonstrating that the statins are active in adipocytes, limit cholesterol formation in the cell, and thus its release into the culture medium.
Negative_regulation (decreases) of apoA-I in adipocytes associated with obesity
9) Confidence 0.34 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.36 Pain Relevance 0
In the first case there was a dramatic decrease in ApoA1 (0.05 g/L), as observed in alcoholic steato-hepatitis.
Negative_regulation (decrease) of ApoA1 associated with hepatitis
10) Confidence 0.33 Published 2006 Journal BMC Gastroenterol Section Body Doc Link PMC1657015 Disease Relevance 1.94 Pain Relevance 0.03
The ApoA1 and PON1 activities were lower in the MCTD/CVD+ and MCTD/CVD- patient groups compared with controls.
Negative_regulation (lower) of ApoA1 associated with cardiovascular disease and systemic sclerosis
11) Confidence 0.32 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911856 Disease Relevance 2.07 Pain Relevance 0
In the second case the absolute value of ApoA1 was not decreased (1.72 g/L) but was relatively low in comparison with HDL cholesterol (1.64 mmol/L).
Neg (not) Negative_regulation (decreased) of ApoA1 associated with disorder of lipid metabolism
12) Confidence 0.12 Published 2006 Journal BMC Gastroenterol Section Body Doc Link PMC1386692 Disease Relevance 1.88 Pain Relevance 0.11
We observed a dramatic decrease in ApoA1 serum levels in patients with alcoholic liver disease which was associated with necrosis, polymorphonuclear infiltrate and Mallory bodies [30].
Negative_regulation (decrease) of ApoA1 in liver associated with necrosis and alcoholic liver diseases
13) Confidence 0.12 Published 2006 Journal BMC Gastroenterol Section Body Doc Link PMC1386692 Disease Relevance 1.54 Pain Relevance 0.07
In the first case there was a dramatic decrease in ApoA1 (0.05 g/L), as observed in alcoholic steato-hepatitis.
Negative_regulation (decrease) of ApoA1 associated with hepatitis
14) Confidence 0.11 Published 2006 Journal BMC Gastroenterol Section Body Doc Link PMC1386692 Disease Relevance 1.75 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox